Is frozen storage really unavoidable for viral vectors — or have we accepted it too easily as the default?

Which development data actually help us predict whether a viral vector drug product will remain stable and functional?

How can we get more development insight from limited viral vector material — without slowing development down?

How can formulation development, stability-indicating analytics and data-driven approaches support more informed development decisions?

What does it take to move from frozen storage as the default toward more robust and practical viral vector drug products?